B. Riley Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $123

B. Riley Securities analyst Madison El-Saadi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $101 to $123.